Ultraviolet (UV), first derivative, second derivative, and AUC-spectrophotometric methods for the determination of letrozole in pharmaceutical formulations have been developed. For UV-spectrophotometry, the standard solutions were measured at 240.0 nm. The linearity ranges were found to be 0.25–20.0 μgml–1 in methanol and the regression equation was A=1.20×10–1C+2.22×10–2(r2=0.9994). For the first derivative spectrophotometry, the response (dA/dλ) of standard solutions was measured at 224.0 nm. The calibration curve was constructed by plotting dA/dλ values against concentrations 0.25–20.0 μgml–1, of letrozole. The regression equation of the linear calibration graph was calculated as D1=3.89×10–3C+1.85×10–4(r2=0.9987). For the second derivative spectrophotometry, the response (d2A/dλ2) of standard solutions was measured at 241.0 nm. The calibration curve was constructed by plotting d2A/dλ2 values against concentrations 0.5–20.0 μgml–1 of letrozole standards in methanol. The regression equation of the linear calibration graph was calculated as D2=-1.59×10–3C-4.66×10–4(r2=0.9985). The AUC-spectrophotometric method was based on the calculation of Area under Curve (AUC), for analysis of letrozole in the wavelength range of 235.0–245.0 nm. The calibration curve was constructed by plotting AUC values against concentrations 0.25–20.0 μgml–1, of letrozole. The regression equation of the linear calibration graph was calculated as AUC=1.132C+0.2153 (r2=0.9994). The methods were validated by following the analytical performance parameters suggested by the International Conference on Harmonization (ICH). All validation parameters were within the acceptable range. The developed methods were successfully applied to estimate the amount of letrozole in pharmaceutical formulations.

No abstract

No abstract

Hyperlipidemia is a prevailing risk factor that leads to development and progression of atherosclerosis and consequently cardiovascular diseases. Several antihyperlipidemic drugs are having various disadvantages such as low water solubility and poor bioavailabilty due to presystemic gastrointestinal clearance. Thus, there is a considerable need for the development of efficient delivery methods and carriers. This review focuses on the importance and role of various nanoparticulate systems as carrier for antihyperlipidemic drugs in the treatment of hyperlipidemia. Some nanoparticle technology-based products are approved by FDA for effective treatment of hyperlipidemia, namely Tricor® by Abbott Laboratories (Chicago, IL, USA) and Triglide® by Skye Pharma (London, UK). Efforts to address each of these issues are going on, and should remain the focus on the future studies and look forward to many more clinical products in the future.

No abstract

No abstract

No abstract

No abstract